Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TBCRC 042 - A Randomized Phase II Window-of-Opportunity Trial of Ruxolitinib in Patients With High Risk and Premalignant Breast Conditions

NCT02928978 is registered in ClinicalTrials.gov with Julie Nangia as lead sponsor.

NCT NCT02928978
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02928978 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TBCRC 042 - A Randomized Phase II Window-of-Opportunity Trial of Ruxolitinib in Patients With High Risk and Premalignant Breast Conditions
Lead sponsor
Julie Nangia
Phase
Phase 2
Overall status
Completed
Start date
May 13, 2018
Completion date
September 18, 2024
Enrollment
84 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

atypical ductal hyperplasia, atypical lobular hyperplasia, ductal carcinoma in situ, lobular carcinoma in situ